Manso, Luís <br/><br/>
Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.  [electronic resource] 

 -  Anticancer research  Dec 2015 
 - 6941-50 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1791-7530 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Cross-Sectional Studies<br/>Female<br/>Humans<br/>Neoplasm Metastasis<br/>Paclitaxel--administration & dosage<br/>Quality of Life<br/>Receptor, ErbB-2--metabolism<br/>Triple Negative Breast Neoplasms--drug therapy